scope of sorafenib tosylate in renal cell carcinoma

  • Annapurna Uppala Department of Pharmaceutics, College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur-522510, Andhra Pradesh
  • Prameela Rani A. Department of Pharmaceutics, College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur-522510, Andhra Pradesh
  • Suresh Y. Department of Pharmaceutics, College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur-522510, Andhra Pradesh
Keywords: kinase inhibitor, long-term treatment, well-tolerated, combination, progression-free survival

Abstract

Renal cell carcinoma  is a kidney cancer that originates in the lining of the proximal convoluted tubule. It  is the most common type of kidney cancer in adults, responsible for approximately 80% of cases. It is also known to be the most lethal of all the genitourinary tumors. Sorafenib received FDA regular approval on December 20, 2005 for the treatment of advanced RCC. Sorafenib belongs to the class of diaryl ethers. Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. The long-term treatment with sorafenib is associated with continued efficacy and a well-tolerated safety profile. It can be used in combination with other antineoplastic drugs effectively. Based on its mechanism of action and findings in animals, sorafenib may cause fetal harm when administered to a pregnant woman. Greater  sensitivity of some older individuals was observed. However, treatment  with sorafenib prolongs progression-free survival in patients with advanced  renal cell carcinoma in whom previous therapy has failed.

 

 

Downloads

Download data is not yet available.

Author Biography

Annapurna Uppala, Department of Pharmaceutics, College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur-522510, Andhra Pradesh

pharmacy

assistant professor

References

Rini B.I, Rathmell W.K and Godley P. Renal cell carcinoma, curr opnion oncol, 20, 300–6, 2008.

Mc Laughlin JK and Lipworth L. Epidemiologic aspects of renal cell cancer, semin oncol, 27, 115-123, 2000.

Kane R.C. Review of oncology and hematology drug product approvals at the US food and drug administration, J Natl Cancer Inst, 24, 230-243, 2010.

Thomas S and Paul R. Journal of Medical Case Reports 4:338, 2010.

Anonymous, http:// en.wikipedia.org/wiki/sorafenib

Ahmad T and Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma, Clinical Cancer Research, 10, 2-18, 2004.

Sebastien H.A systematic review on renal cell carcinoma, Canadian Urological Association Journal, 1, 27-38, 2007.

Thomas E, Huston, Joaquim B and Camillo P. A review on Long-term safety of sorafenib in advanced renal cell carcinoma, Eur. J. of Cancer, 46, 2432-2440, 2010.

Mila P, Zhasmina M and Alben F. A mini review of sorafenib in metastatic, MTC-medullar thyroid cancer, International Medical Case Reports Journal, 3, 55-58, 2010.

Lettieri J.T, Dubowy R, Xia C, Rotolo C and Zinny M.A, Journal of Clinical Oncology, 27, No 15S, 2009.

http://www.pharmainfo.net

http://www.rxlist.com/nexavar-drug.hmt

Published
2015-06-09
Issue
Vol 1 No 1 (2015): IEJPS
Section
Review Articles

Copyright (c) 2015 Indian E-Journal of Pharmaceutical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).